When pharmaceutical company Moderna issued a press release about the promising results of its Phase I clinical trial for a coronavirus vaccine, the media and the markets went wild. Upon examining Moderna's non-peer reviewed press release, the actual data on the vaccine's success is ... flimsy. Of the 45 patients who received the vaccine, the data on "neutralising antibody data are available only for the first four participants in each of the 25-microgram and 100-microgram dose level cohorts." In other words, that means that when it comes to finding out whether the vaccine elicits an antibody response that could potentially fight the coronavirus, they only had data on eight patients. That's not enough to do any type of statistical analysis and it also brings into question the status of the other 37 patients who also received the vaccine. Moderna's messenger RNA vaccine ... uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells' protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus. There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions. Messenger RNA vaccines have never before been brought to market for human patients.